Cambrex Corporation (NYSE:CBM) Position Cut by Amalgamated Bank

Amalgamated Bank cut its position in Cambrex Corporation (NYSE:CBM) by 0.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,215 shares of the biotechnology company’s stock after selling 11 shares during the period. Amalgamated Bank’s holdings in Cambrex Corporation were worth $232,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Flinton Capital Management LLC increased its position in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 68 shares during the last quarter. YorkBridge Wealth Partners LLC increased its stake in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 315 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Cambrex Corporation during the first quarter valued at about $109,000. Dubuque Bank & Trust Co. acquired a new stake in shares of Cambrex Corporation during the first quarter valued at about $144,000. Finally, Ameritas Investment Partners Inc. acquired a new stake in shares of Cambrex Corporation during the first quarter valued at about $151,000. 98.28% of the stock is currently owned by hedge funds and other institutional investors.

Cambrex Corporation (NYSE:CBM) traded down 1.15% on Friday, hitting $51.40. 196,401 shares of the stock were exchanged. The company has a market capitalization of $1.68 billion, a PE ratio of 18.72 and a beta of 2.28. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95. The company has a 50-day moving average price of $57.39 and a 200 day moving average price of $55.47.

Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.76. The business had revenue of $134.55 million for the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.68 EPS. Analysts anticipate that Cambrex Corporation will post $3.08 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Cambrex Corporation (NYSE:CBM) Position Cut by Amalgamated Bank” was originally reported by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/cambrex-corporation-nysecbm-position-cut-by-amalgamated-bank-updated-updated-updated.html.

Several equities research analysts have recently issued reports on CBM shares. Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. BidaskClub upgraded shares of Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Finally, ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cambrex Corporation presently has a consensus rating of “Buy” and a consensus target price of $64.00.

In other news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $54.19, for a total value of $650,280.00. Following the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Samantha Hanley sold 14,000 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $57.56, for a total transaction of $805,840.00. Following the completion of the sale, the vice president now directly owns 1,500 shares in the company, valued at $86,340. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,656 shares of company stock worth $4,064,423. Insiders own 2.48% of the company’s stock.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply